IMDX Insight Molecular Diagnostics Inc.
Healthcare$6.44+5.75%ClosedMarket Cap: $172.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-20.79
P/S
88.69
EV/EBITDA
-2.87
DCF Value
$-2.91
FCF Yield
-15.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.5%
Operating Margin
-2112.4%
Net Margin
-2454.6%
ROE
380.8%
ROA
-118.3%
ROIC
-136.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $32.0K | -1892.2% | $-10.3M | $-4.3M | $— | — |
| Q4 null | $1.1M | 43.5% | $-9.9M | $-23.0M | $— | — |
| FY null | $4.1M | 4.7% | $-30.6M | $-50.2M | $— | — |
| Q3 null | $260.0K | 53.5% | $-11.0M | $-10.9M | $— | — |
| Q2 null | $518.0K | 67.6% | $-9.8M | $-9.7M | $— | — |
| Q1 null | $2.1M | 62.0% | $-6.8M | $-6.7M | $— | — |
| Q4 null | $1.5M | 40.0% | $-33.6M | $-33.5M | $— | — |
| FY null | $1.9M | 39.3% | $-61.0M | $-60.7M | $— | — |
| Q3 null | $115.0K | 43.5% | $-13.5M | $-13.5M | $— | — |
| Q2 null | $104.0K | 48.1% | $-4.6M | $-4.5M | $— | — |
| Q1 null | $176.0K | 25.6% | $-9.3M | $-9.1M | $— | — |
| Q4 2023 | $314.0K | -30.3% | $-16.2M | $-16.0M | $-1.96 | — |